OOIR: Observatory of International Research

Papers

(The H4-Index of Multiple Sclerosis Journal is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Time to move past typical syndromes in the diagnosis of multiple sclerosis	69
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary	68
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary	67
Reply to letter to the editor: Olfactory threshold as a biomarker of disease activity	57
Therapy challenges for NMOSD in a patient with HIV	57
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient	55
Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No	54
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Yes	54
Sars-CoV2 infection in pregnant women with multiple sclerosis	54
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO	48
Thematic analysis of multiple sclerosis research by enhanced strategic diagram	44
Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline	43
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis	40
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series	40
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study	39
Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years	37
GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis	34
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity	34
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions	33
Decentralised clinical trials in multiple sclerosis research	33
An interdisciplinary approach is necessary in the treatment of cognitive decline in MS: No	32
Double-negative neuromyelitis optica spectrum disorder	31
Productivity loss among people with early multiple sclerosis: A Canadian study	30
Erratum to “Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis” Multiple Sclerosis Journal; 2024: 30(8); 1086–1088. DOI: 10.1177/13524585241260564.	30
Cerebrospinal fluid–related tissue damage in multiple sclerosis patients with iron rim lesions	29

Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study	29
The MoXFo initiative – study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis	29
To halt disease progression rehabilitation in MS should start early: Yes	28